Geographic Atrophy (GA) Resources
Geographic atrophy (GA) is the relentlessly progressive, irreversible, advanced form of dry age-related macular degeneration (AMD) and affects approximately 1 million people in the United States.1 GA is characterized by atrophic lesions in the outer retina.2,3 Lesions in GA lead to irreversible vision loss.3
AMCP is pleased to work with Apellis Pharmaceuticals, Inc., to offer these resources to you.
Science and Innovation Webinar
Webinar Recorded on June 28, 2022
Sponsored by Apellis Pharmaceuticals, Inc.
Over 1 million people in the United States are affected by a relentlessly progressive condition, known as geographic atrophy (GA), that can lead to irreversible vision loss with no current FDA‑approved treatment options. This webinar focuses on GA—the advanced form of dry age-related macular degeneration (AMD) that is characterized by atrophic lesions in the central region of the macula. Join us to learn more about the prevalence, characteristics, and disease progression of GA.
©2022 Apellis Pharmaceuticals, Inc. All rights reserved. 07/22 US-GA-2200253 v1.0
Philip J. Ferrone, MD, FASRS
President, American Society of Retina Specialists
Attending physician, Vitreoretinal Consultants of New York
Professor of ophthalmology, Hofstra/Northwell
Adjunct assistant professor of ophthalmology, Columbia University
Sponsored by Apellis
1. Friedman DS, O'Colmain BJ, Muñoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
2. Kaszubski P, Ben Ami T, Saade C, Smith RT. Geographic atrophy and choroidal neovascularization in the same eye: a review. Ophthalmic Res. 2016;55(4):185-193.
3. Fleckenstein M, Mitchell P, Freund KB, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125(3):369-390.
©2022 Apellis Pharmaceuticals, Inc. All rights reserved. 07/22 US-GA-2200274 v1.0